|
|
|
|
|
|
|
|
abstract
Aim
Ovarian
cancer is the second most common gynecological malignancy, yet it has
the highest case-fatality ratio of all gynecologic malignancies. Surgery
followed by combination platinum-taxane chemotherapy is the standard
approach to the management of primary epithelial ovarian cancer.
However, standard treatment of patients with recurrent ovarian cancer
remains poorly defined. Secondary cytoreductive surgery (SDS) at the
time of relapse has been proposed as a means of improving the prognosis
of recurrent ovarian cancer patients with a treatment-free interval of
at least 6 months.
Methods
In
the present study, we retrospectively collected 16 patients with
recurrent epithelial ovarian cancer who might benefit most from SDS and
evaluated the impact of SDS on the outcomes for this highly select
patient group.
Results
We
found that SDS led to excellent outcomes, with a 73.1% 8-year overall
survival rate after initial treatment, a 67.9% 5-year overall survival
rate after prior SDS, and a 31.3% 5-year progression-free survival rate
after prior SDS. Although the findings were not significant, these
results suggest that repeated SDS might improve outcomes for this
patient group.
Conclusion
The
present study may provide a platform for discussion of the impact of
aggressive or repeated SDS on the survival of patients with recurrent
epithelial ovarian cancer and favorable prognostic factors. Further
multi-institutional studies with larger number of patients are mandatory
to confirm the present findings.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.